Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial

Inclusion Criteria: * Signed written informed consent * Male or female subjects， 18-75 years of age * Medically accepted effective contraception if procreative potential exists * Diagnosis of histologically confirmed adenocarcinoma of the colon or rectum * RAS wild-type and BRAF-V600E wild-type status in tumor tissue * At least one measurable lesion by computer tomography (CT) or magnetic resonance imaging (MRI) according to RECIST * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at trial entry * Life expectancy of at least 12 weeks * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at trial entry * White blood cell count \>= 3 × 10x9/L with neutrophils \>= 1.5 × 10x9/L, platelet count \>=75 × 10x9/L and hemoglobin \>= 8 g/dL； Total bilirubin \<= 1.5 × upper limit of reference range， Aspartate transaminase (AST) and alanine transaminase (ALT) \<= 2.5 × upper limit of reference range or \<= 5 × upper reference range in subjects with liver metastasis；Serum creatinine \<= 1.5 × upper limit of reference range Exclusion Criteria: * Known hypersensitivity or allergic reactions against any of the components of the trial treatments * Radiotherapy or surgery (excluding prior diagnostic biopsy) in the 28 days before trial treatment * Known brain metastasis and/or leptomeningeal disease. Subjects with neurological symptoms should undergo a CT scan/MRI of the brain to exclude brain metastasis * Acute or sub-acute intestinal occlusion or hi…